Impact of Different Carbapenems and Regimens of Administration on Resistance Emergence for Three Isogenic Pseudomonas aeruginosa Strains with Differing Mechanisms of Resistance
- 1 June 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (6), 2638-2645
- https://doi.org/10.1128/aac.01721-09
Abstract
We compared drugs (imipenem and doripenem), doses (500 mg and 1 g), and infusion times (0.5 and 1.0 [imipenem], 1.0 and 4.0 h [doripenem]) in our hollow-fiber model, examining cell kill and resistance suppression for three isogenic strains of Pseudomonas aeruginosa PAO1. The experiments ran for 10 days. Serial samples were taken for total organism and resistant subpopulation counts. Drug concentrations were determined by high-pressure liquid chromatography-tandem mass spectrometry (LC/MS/MS). Free time above the MIC (time > MIC) was calculated using ADAPT II. Time to resistance emergence was examined with Cox modeling. Cell kill and resistance emergence differences were explained, in the main, by differences in potency (MIC) between doripenem and imipenem. Prolonged infusion increased free drug time > MIC and improved cell kill. For resistance suppression, the 1-g, 4-h infusion was able to completely suppress resistance for the full period of observation for the wild-type isolate. For the mutants, control was ultimately lost, but in all cases, this was the best regimen. Doripenem gave longer free time > MIC than imipenem and, therefore, better cell kill and resistance suppression. For the wild-type organism, the 1-g, 4-h infusion regimen is preferred. For organisms with resistance mutations, larger doses or addition of a second drug should be studied.This publication has 8 references indexed in Scilit:
- Mechanisms of carbapenem resistance in non-metallo-β-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospitalPathologie Biologie, 2009
- Pharmacokinetic–pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patientsDiagnostic Microbiology and Infectious Disease, 2009
- Impact of Short‐Course Quinolone Therapy on Susceptible and Resistant Populations ofStaphylococcus aureusThe Journal of Infectious Diseases, 2009
- Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study*Critical Care Medicine, 2008
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006
- Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2005
- Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection PotentialAntimicrobial Agents and Chemotherapy, 2004
- Prevention of Resistance: A Goal for Dose Selection for Antimicrobial AgentsClinical Infectious Diseases, 2003